Open Access Open Access  Restricted Access Subscription or Fee Access

Beyond Chemotherapy: The Promise of Immunotherapy in Cancer Care and Advancements in Cancer Therapy

Zaid Khan

Abstract


Recent advances in cancer immunotherapy harness the immune system to precisely target cancer. These include the use of immunosuppressive agents, NK cell recovery, changes in tumor microenvironment metabolic, and aging to achieve a positive tumor response The article explores how the body development of the immune system in the late 19th century, highlighting milestones such as the discovery and FDA approval of IL2. Different categories of immunology are explored, from monoclonal antibodies to CAR-T cell therapies, with emphasis on potential and challenges. It emphasizes the role of the immune system in cancer prevention and includes drugs that block the immune system, such as PD-1/PD-L1 and CTLA-4 blockers , their approaches, clinical success, and combination therapies are discussed The promising field of CAR-T cell therapy is broad, including technology, product development, challenges, future prospects and availability. In addition, oncolytic viruses such as T-VEC and HSV-1-based therapy show promise in cancer treatment. Ongoing research has been published on the treatment of oncolytic viruses for a variety of cancers, including triple negative breast cancer. Although challenges such as resistance to therapy remain, future developments include neoantigen vaccines, personalized medicine and nanomedicines to enhance drug delivery and reduce side effects Immunotherapy dramatically extends patients' lives and improves their quality of life, offering hope for advanced cancer treatment.

Keywords


Immunotherapy, cancer care, quality of life, Natural Killer (NK) cells, Cytokine-based therapies, Tumor antigen escape.

Full Text:

PDF

References


Aydin, Ahmet Murat, et al. "Prognostic significance of pre-and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy." World journal of urology 38 (2020): 2537-2545.

Hosseini, Reza, et al. "Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy." Molecular Cancer 21.1 (2022): 1-18.

Zhao, Lin, et al. "Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer." Cell Death & Disease 13.4 (2022): 378.

Paffenholz, Stella V., et al. "Senescence induction dictates response to chemo-and immunotherapy in preclinical models of ovarian cancer." Proceedings of the National Academy of Sciences 119.5 (2022): e2117754119.

Zhang, Yuanyuan, and Zemin Zhang. "The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications." Cellular & molecular immunology 17.8 (2020): 807-821.

Allison, J. P. "A brief history of immunotherapy." Target. Oncol. 3 (2014).

Development of Cancer Immunotherapy | Center for Cancer Research.ccr.cancer.gov/news/landmarks/article/development-of-cancer-immunotherapy.

Allison, J. P. "A brief history of immunotherapy." Target. Oncol. 3 (2014).

Khan, Meshaal, Ajay V. Maker, and Shikha Jain. "The evolution of cancer immunotherapy." Vaccines 9.6 (2021): 614.

“History of Cancer Treatments: Immunotherapy.” American Cancer Society, www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-immunotherapy.html.

Darvishi, Mohammad, et al. "Recent progress in cancer immunotherapy: Overview of current status and challenges." Pathology-Research and Practice (2022): 154241.

Fa’ak, Faisal, and Adi Diab. "Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors." Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy: A Handbook for Diagnosis and Management (2021): 31-47.

Caruso, Dean. “Current and future directions for cancer immunotherapy Overview 102.” (2015).

Beckhove, Philipp. "Cancer immunotherapy: overview in brief." The Tumor Immunoenvironment (2013): 549-565.

Tan, Wei Chang Colin, et al. "Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy." Cancer Communications 40.4 (2020): 135-153.

Timmer, Florentine EF, et al. "Pancreatic cancer and immunotherapy: a clinical overview." Cancers 13.16 (2021): 4138. 17.Mezni, Essia, Khalil Behi, and Anthony Gonçalves. "Immunotherapy and breast cancer: An overview." Current Opinion in Oncology 34.5 (2022): 587-594.

Li, Xinxin, et al. "Targeting the RNA m6A modification for cancer immunotherapy." Molecular Cancer 21.1 (2022): 76.

Creemers, Jeroen HA, et al. "A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery." Journal for ImmunoTherapy of Cancer 9.5 (2021).

Sethna, Zachary, et al. "824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors." (2021).

Bullock, Timothy NJ. "Fundamentals of cancer immunology and their application to cancer vaccines." Clinical and Translational Science 14.1 (2021): 120-131.

Vu, Tamara MSH, et al. "Theranostics: a fifth pillar of contemporary cancer care?." ANZ Journal of Surgery 92.11 (2022): 2782.

Deng, Yixin et al. “Introduction and Application of Death Protein 1.” 2022 International Conference on Biotechnology, Life Science and Medical Engineering (BLSME 2022) (2022).

Huang, Haoran, et al. "T cell proliferation-related genes: Predicting prognosis, identifying the cold and hot tumors, and guiding treatment in clear cell renal cell carcinoma." Frontiers in Genetics 13 (2022): 948734.

Sharifi, Maryam, Arta A. Jamshidi, and Nazanin Namazi Sarvestani. "An adaptive robust control strategy in a cancer tumor-immune system under uncertainties." IEEE/ACM Transactions on Computational Biology and Bioinformatics 16.3 (2018): 865-873.

Ertan, Kubra, et al. "The importance of systemic inflammatory response index, systemic immune-inflammation index, and hemoglobin-albumin-lymphocytes-platelets (HALP) score in children with cancer." Iranian Journal of Pediatrics 31.6 (2021).

Ertan, Kubra, et al. "The importance of systemic inflammatory response index, systemic immune-inflammation index, and hemoglobin-albumin-lymphocytes-platelets (HALP) score in children with cancer." Iranian Journal of Pediatrics 31.6 (2021).

Dang, Yangjie, et al. "The effect of anesthesia on the immune system in colorectal cancer patients." Canadian Journal of Gastroenterology and Hepatology 2018 (2018).

Kaur, K. K., G. Allahbadia, and M. Singh. "Importance of controlling obesity and associated immune response changes in prevention and treatment of cancer–with plant therapies of help." Adv Obes Weight Manag Control 9.4 (2019): 114-116.

Ahlmann, Martina, and Georg Hempel. "The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy." Cancer chemotherapy and pharmacology 78 (2016): 661-671.

Nair, Varun Sasidharan, et al. "Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients." Epigenomics 12.21 (2020): 1871-1882. 32.Wang, Ping-Huai, et al. "The dynamic change of immune checkpoints and CD14+ monocytes in latent tuberculosis infection." Biomedicines 9.10 (2021): 1479.

Funes, Samanta C., et al. "Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy." Autoimmunity Reviews 18.4 (2019): 359-368.

Hu, Min, et al. "The regulation of immune checkpoints by the hypoxic tumor microenvironment." PeerJ 9 (2021): e11306.

Ruedas-Torres, Inés, et al. "Up-regulation of immune checkpoints in the thymus of PRRSV-1-infected piglets in a virulence-dependent fashion." Frontiers in Immunology 12 (2021): 671743.

Shang, Bing-Bing, et al. "Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma." PeerJ 9 (2021): e12315.

Sasikumar, Pottayil G., and Murali Ramachandra. "Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development." Frontiers in Immunology 13 (2022): 752065.

Godwin, James L., et al. "Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials." Discovery medicine 18.101 (2014): 341-350.

Zhou, Xiaohan, et al. "Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality." Frontiers in oncology 10 (2020): 1321. 40.Tenorio-Pedraza, Juan Miguel, et al. "Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates." Translational Medicine Communications 8.1 (2023): 17.

Tang, Xuzhen, et al. "HuPBL humanized models as a tool to evaluate the efficacy and immune regulation of immune checkpoint inhibitors." Cancer Research 77.13_Supplement (2017): 3849-3849. 42.Guo, Linlin, et al. "A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)." Oncoimmunology 11.1 (2022): 2127691.

Chyuan, I-Tsu, Ching-Liang Chu, and Ping-Ning Hsu. "Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies." Cancers 13.6 (2021): 1188.

Puri, Sonam, and Michael Shafique. "Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies." Drugs in context 9 (2020).

Cheu, Jacinth Wing‐Sum, and Carmen Chak‐Lui Wong. "Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors." Hepatology 74.4 (2021): 2264-2276.

Maung, Tun Zan, et al. "Immune checkpoint inhibitors in lung cancer: role of biomarkers and combination therapies." Cureus 12.5 (2020).

Palmer, Adam C., et al. "Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors." Clinical Cancer Research 28.2 (2022): 368-377.

Gong, Jun, et al. "Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade." Clinical and translational medicine 7 (2018): 1-16.

Pagel, John M., and Howard Jack West. "Chimeric antigen receptor (CAR) T-cell therapy." JAMA oncology 3.11 (2017): 1595-1595.

Zhang, C., and A. Kasi. "Chimeric Antigen Receptor (CAR) T-Cell Therapy." StatPearls: Treasure Island, FL (2019).

Hofmann, Susanne, et al. "Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)." Journal of clinical medicine 8.2 (2019): 200.

Sakoda, Yukimi, and Koji Tamada. "Chimeric antigen receptor (CAR)-T cell therapy." Nihon rinsho. Japanese Journal of Clinical Medicine 75.2 (2017): 281-287.

Schubert, M-L., et al. "Side-effect management of chimeric antigen receptor (CAR) T-cell therapy." Annals of oncology 32.1 (2021): 34-48.

Fraietta, Joseph A., et al. "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia." Nature medicine 24.5 (2018): 563-571.

Dimitri, Alexander, Friederike Herbst, and Joseph A. Fraietta. "Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing." Molecular Cancer 21.1 (2022): 78.

Wagner, Dimitrios L., et al. "sustainable clinical development of CAR-T cells–switching from viral transduction towards CRISPR-Cas gene editing." Frontiers in Immunology 13 (2022): 865424.

Agarwalla, Pritha, et al. "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells." Nature biotechnology 40.8 (2022): 1250-1258.

Larson, Rebecca C., and Marcela V. Maus. "Recent advances and discoveries in the mechanisms and functions of CAR T cells." Nature Reviews Cancer 21.3 (2021): 145-161.

Huckaby, Justin T., et al. "Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells." Journal for Immunotherapy of Cancer 9.9 (2021).

El-Daly, Sherien M., and Jihan Hussein. "Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions." Journal of Applied Biomedicine 17.1 (2019): 11-11.

Poorebrahim, Mansour, et al. "Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects." Critical reviews in clinical laboratory sciences 56.6 (2019): 393-419.

Srour, Samer A., and Serkan Akin. "Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future." Journal of Immunotherapy and Precision Oncology 6.1 (2023): 19-30.

Gor, Dhairya, et al. "The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma." European Journal of Case Reports in Internal Medicine 9.7 (2022).

Golubovskaya, Vita, et al. "Major highlights of the CAR-TCR Summit, Boston, 2016." Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 17.10 (2017): 1344-1350.

Beck, Caroline, et al. "Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges." Current gene therapy 4.4 (2004): 457-467.

Lauer, Ulrich M., and Julia Beil. "Oncolytic viruses: challenges and considerations in an evolving clinical landscape." Future Oncology 18.24 (2022): 2713-2732.

Rahman, Masmudur M., and Grant McFadden. "Oncolytic viruses: newest frontier for cancer immunotherapy." Cancers 13.21 (2021): 5452.

Tian, Yaomei, Daoyuan Xie, and Li Yang. "Engineering strategies to enhance oncolytic viruses in cancer immunotherapy." Signal Transduction and Targeted Therapy 7.1 (2022): 117.

Heidbuechel, Johannes PW, and Christine E. Engeland. "Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies." Journal of hematology & oncology 14.1 (2021): 1-24.

Malogolovkin, Alexander, et al. "Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes." Viruses 13.7 (2021): 1271.

Suryawanshi, Yogesh R., and Autumn J. Schulze. "Oncolytic viruses for malignant glioma: On the verge of success?." Viruses 13.7 (2021): 1294.

Goins, William F., et al. "Engineering HSV-1 vectors for gene therapy." Herpes Simplex Virus: Methods and Protocols (2014): 63-79.

Goins, William F., et al. "Engineering HSV-1 vectors for gene therapy." Herpes simplex virus: Methods and protocols (2020): 73-90.

Marinova, Zhenya, et al. "Oncolytic virotherapy-can a poliovirus cure cancer?." Scripta Scientifica Pharmaceutica 3 (2016): 12.

Ye, Levitin, et al. "Scripta Scientifica Pharmaceutica, 2015, Vol. 1, pp. 39-45." (2016).

Li, Mengyuan, et al. "Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review." Cancer Biology & Medicine 20.9 (2023): 646.

Jin, Shengye, et al. "Oncolytic viruses for triple negative breast cancer and beyond." Biomarker Research 9 (2021): 1-16.

Alayo, Quazim, et al. "IMMU-12. THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID AUGMENTS THE SUSCEPTIBILITY OF ONCOLYTIC VIRUS-INFECTED GLIOBLASTOMA CELLS TO PD-1 BLOCKADE THERAPY." Neuro-Oncology 19.Suppl 6 (2017): vi115.

Goradel, Nasser Hashemi, et al. "Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses." Future Oncology 18.2 (2021): 245-259.

Miller, Megan Jo, Kevin Chu Foy, and Pravin TP Kaumaya. "Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics." Discovery medicine 15.82 (2013): 166-176.

Peña, Quim, et al. "Metallodrugs in cancer nanomedicine." Chemical Society Reviews 51.7 (2022): 2544-2582.

Wurster, Sebastian, Stephanie S. Watowich, and Dimitrios P. Kontoyiannis. "Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions." Frontiers in immunology 13 (2022): 1018202.

Pan, Ren-You, et al. "Recent development and clinical application of cancer vaccine: targeting neoantigens." Journal of immunology research 2018 (2018).

Van Allen, Eliezer. "Abstract SY18-02: Immunogenomics and precision cancer medicine." Cancer Research 76.14_Supplement (2016): SY18-02.

Zhang, Ning. "Promoting the bench-to-bedside translation of nanomedicines." Medical Review 3.1 (2023): 1-3.

Amin, Saber, et al. "Impact of immunotherapy on the survival of patients with cancer and brain metastases." Journal of the National Comprehensive Cancer Network 18.7 (2020): 832-840.

Beaulieu, Elizabeth, et al. "Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams." Quality of life research 31.8 (2022): 2357-2366.

Kim, Hongsik, et al. "Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)." Cancer 128.4 (2022): 778-787.

Fragkiadakis, Georgios F., et al. "Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases." Cureus 14.12 (2022).

“Long-Term Side Effects of Immune Checkpoint Inhibitors.” National Cancer Institute, 30 Apr. 2021, www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects.




DOI: https://doi.org/10.37591/rrjoi.v13i2.3323

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Immunology